1. Show article details.

    Health-Care Startups Raise Record $3.89 Billion in Venture Capital in First Quarter

    DJ Business News – 12:40 PM ET 04/21/2015

    U.S. medical startups raised a record $3.9 billion in venture capital in the first quarter of 2015 amid rising investor interest in biotechnology, digital health and health-care services. The total surpassed the previous record high of $3.42 billion invested in the second quarter of 2014, according to data provider Dow Jones VentureSource. A strong market for initial public offerings, growing confidence in the success of drugs in clinical trials and acquisitions by large...

  2. Show article details.

    Nodality Publishes Study Results Confirming the Company’s Diagnostic Can Predict Induction Therapy Response in Elderly Patients with Acute Myeloid Leukemia

    Business Wire – 8:00 AM ET 04/21/2015

    Nodality, Inc., today announced publication of data in the journal PLOS ONE detailing the clinical validation of the Company’s Single Cell Network Profiling-based diagnostic classifier for prediction of response to standard induction therapy (cytarabine-based chemotherapy) in elderly patients with Acute Myeloid Leukemia.

  3. Show article details.

    U.S. Firms Urge China to Improve Conditions

    DJ Business News – 6:35 AM ET 04/21/2015

    BEIJING-U.S. businesses are pushing Chinese authorities to improve legal transparency, market access and intellectual- property rights across industries from technology to pharmaceuticals after foreign companies faced a spate of new regulatory hurdles in the country recently. The American Chamber of Commerce in China is urging Chinese leaders to improve working conditions for information and communications technology, ensuring rule of law and creating...

  4. Show article details.

    IBM Reports Another Revenue Decline

    DJ Business News – 4:35 PM ET 04/20/2015

    For most of its 104- year history, International Business Machines Corp. (IBM)' s lifeblood has been business hardware: cheese slicers and card punches in the early days, mainframe computers and microchips of late. As hardware sales have shrunk, though, the company has bet its future on software and services--a strategy that has yet to bear fruit. Hardware sales continued their slide in the first quarter.

  5. Show article details.

    IBM Reports Another Revenue Decline

    DJ Business News – 4:32 PM ET 04/20/2015

    International Business Machines Corp. (IBM) reported a 12% decrease in revenue--the company's 12th straight quarter of year-over-year declines--hurt by the stronger U.S. dollar and weakness in its hardware business. For the year, the company reiterated its estimate for per-share profit, excluding certain items, between $15.75 and $16.50. Shares rose 0.4% to $166.87 in recent after-hours trading as the company's first-quarter per-share earnings exceeded expectations.

  6. Show article details.

    Johnson & Johnson to Host Pharmaceutical Business Review

    PR Newswire – 2:20 PM ET 04/20/2015

    NEW BRUNSWICK, N.J., April 20, 2015 Johnson & Johnson (JNJ) will host a review of its Pharmaceutical business for the investment community beginning at 8:30 a.m. on Wednesday, May 20, 2015 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 3:00 p.m. Paul Stoffels, M.D., Worldwide Chairman Pharmaceuticals, and Chief Scientific Officer and Joaquin Duato, Worldwide Chair...

  7. Show article details.

    BRIEF-Genmab reach $10 mln milestone in Johnson & Johnson collaboration

    Reuters – 9:55 AM ET 04/16/2015

    Genmab (GNMSF). * Says achieves 10 million dollar milestone in daratumumab collaboration with Janssen, a pharmaceutical company of Johnson & Johnson (JNJ). * Says has reached fifth milestone in its daratumumab collaboration with Janssen. * Says the news does not impact its 2015 financial guidance Source text for Eikon: Further company coverage:

  8. Show article details.

    J&J's Drug Treatment for the Dollar

    MarketWatch – 9:32 PM ET 04/14/2015

    The strong dollar inflicted a flesh wound on Johnson& Johnson. The question is whether pharmaceuticals can salve the stock price. The health care giant on Tuesday reported international sales fell 12.4% year over year to $8.7 billion in the first quarter.

  9. Show article details.

    Intel shares rise on in-line earnings report

    MarketWatch – 7:04 PM ET 04/14/2015

    By Wallace Witkowski and Sue Chang, MarketWatch. CSX shares advance on earnings beat, dividend hike. Intel (INTC) shares rose 2.7% to $32.35 on heavy volume on a fiscal second-quarter profit of 41 cents a share.

  10. Show article details.

    Aduro IPO pricing values drugmaker at $1 bln

    Reuters – 6:23 PM ET 04/14/2015

    Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion. The upsized offering, which was priced on par with the company's expectation, raised about $119 million.

  11. Show article details.

    Aduro Biotech IPO priced at $17 per share - underwriter

    Reuters – 5:46 PM ET 04/14/2015

    Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion. The upsized offering, which was priced on par with the company's expectation, raised about $119 million. Aduro, which counts Johnson & Johnson (JNJ) and Novartis AG (NVS) among its investors, is selling all the 7 million shares in the offering.

  12. Show article details.

    U.S. Stocks Trade Mostly Higher

    DJ Business News – 3:46 PM ET 04/14/2015

    U.S. stocks were mostly higher Tuesday, as oil prices rose and investors eyed first-quarter earnings reports from J.P. Morgan Chase& Co. and others. The Dow Jones Industrial Average rose 80 points, or 0.5%, to 18059 in afternoon trade.

  13. Show article details.

    US STOCKS-Wall Street moves higher, led by energy shares

    Reuters – 1:26 PM ET 04/14/2015

    * Energy companies push stocks higher. * Norfolk Southern (NSC) gives weak outlook, shares fall. * Expectations low as earnings season picks up. * Dow up 0.44 pct, S&P up 0.16, Nasdaq down 0.31 pct. By Noel Randewich.

  14. Show article details.

    US STOCKS-Wall St turns lower as earnings concerns linger

    Reuters – 11:34 AM ET 04/14/2015

    * JPMorgan (JPM) rises after results, Wells Fargo (WFC) lower. * Norfolk Southern (NSC) gives weak outlook, shares fall. * Nokia (NOK) in talks to buy Alcatel-Lucent. * Dow up 0.2 pct, S&P flat, Nasdaq down 0.3 pct. By Ryan Vlastelica.

  15. Show article details.

    U.S. Stocks Edge Higher

    DJ Business News – 10:10 AM ET 04/14/2015

    U.S. stocks crept higher Tuesday, as investors eyed first-quarter earnings reports from J.P. Morgan Chase& Co. and others. Morgan posted the biggest gains in the Dow Jones Industrial Average, which rose 43 points, or 0.2%, to 18024 in early trading.

  16. Show article details.

    US STOCKS-Wall St edges up after JPMorgan, J&J results

    Reuters – 9:47 AM ET 04/14/2015

    * JPMorgan (JPM) rises after results, Wells Fargo (WFC) lower. * Norfolk Southern (NSC) gives weak outlook, shares fall. * Nokia (NOK) in talks to buy Alcatel-Lucent. * Indexes up: Dow 0.3 pct, S&P 0.2 pct, Nasdaq 0.1 pct. By Ryan Vlastelica.

  17. Show article details.

    U.S. Stock Futures Trade Little Changed

    DJ Business News – 9:10 AM ET 04/14/2015

    U.S. stock futures were little changed Tuesday as investors eyed first-quarter earnings reports from J.P. Morgan Chase& Co. and other companies. S&P 500 futures lost three points, or 0.1%, to 2084. E-mini Dow futures slipped 12 points, or 0.1%, to 17898, and e-mini Nasdaq-100 futures fell one point to 4402..

  18. Show article details.

    US STOCKS-Futures point to flat open after JPMorgan, J&J results

    Reuters – 9:05 AM ET 04/14/2015

    * JPMorgan (JPM) rises in premarket after results. * Norfolk Southern (NSC) gives weak outlook, shares fall. * Nokia (NOK) in talks to buy Alcatel-Lucent. * Futures: Dow down 3 pts, S&P down 2 pts, Nasdaq up 1.5 pt. By Ryan Vlastelica.

  19. Show article details.

    Why it may be time to start believing in banks again

    MarketWatch – 8:55 AM ET 04/14/2015

    Critical information ahead of the market's open. "It marks the period of the year when you actively cheat on your spouse, run about the Hamptons with cocaine in your noses, and drink yourselves into a coma. On the other hand, you also get smoked in the stock market, "writes The Fly.

  20. Show article details.

    J&J Profit, Outlook Fall Amid Stronger Dollar

    DJ Business News – 8:25 AM ET 04/14/2015

    A stronger U.S. dollar and weak medical-device sales pressured Johnson& Johnson's first-quarter results and full-year outlook, while the health-care giant leaned on its growing pharmaceutical unit to partially offset declines in other segments. J&J said Tuesday its first-quarter profit dropped 8.6% while sales declined 4.1% from a year earlier. The New Brunswick, N.J., company, which derives half of its revenue from outside the U.S., also trimmed its full-year 2015 earnings...

Page:

Today's and Upcoming Events

  • Apr
    23

    Shareholders Meeting

  • Jul
    14

    JNJ to announce Q2 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Apr
    14

    JNJ Earnings Conference Call at 8:30 AM Listen

  • Feb
    20

    JNJ ex-Dividend for $0.70 on 2/20/2015

    • Announce Date: 1/5/2015
    • Record Date: 2/24/2015
    • Pay Date: 3/10/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.